Resumen de: AU2020200824A1

This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule. See Fig. 1.

Resumen de: WO2020036529A1

The present invention relates to a nanogel of nanoparticles. The nanoparticles comprise self-assembled dendritic containing polymers having at least one dendritic hydrophobic segment forming the core and at least one hydrophilic segment forming the shell.

Resumen de: WO2020034696A1

The present invention relates to a traditional Chinese medicine-magnetic nano-cluster chemical immunity drug delivery system and a preparation method therefor, comprising superparamagnetic oxide nanoparticles; a drug and a TAMs-targeting ligand are anchored to a surface of the superparamagnetic oxide nanoparticles; the superparamagnetic magnet oxide nanoparticles form a nanocluster structure by means of disulfide bonds; and the nanocluster structure is packaged by a protein. The traditional Chinese medicine-magnetic nano-cluster chemical immunity drug delivery system of the present invention integrates the targeting advantages of magnetic trending, ligand modification, and reduction sensitivity, and is a traditional Chinese medicine chemical immunity drug delivery system having stable internal circulation, highly efficient tumor accumulation and precise TAMs targeting.

Resumen de: WO2020036266A1

The present invention relates to a nanoliposome preparation method for forming nanoliposomes by emulsifying horse oil and nanodiamonds by means of lecithin, nanoliposomes in which a biologically active and functional plant-extract substance is bound and comprised in defective parts of the nanodiamonds, and a pharmaceutical or cosmetic composition comprising same. Since the surface detachment of a biologically active material occurs in small amounts over a long period of time, the duration of pharmacological action is very long and thus a liposome composition providing lasting and continuous biological activity can be provided.

Resumen de: WO2020034001A1

This invention is directed to nanoparticles for delivery of nucleic acids to target cells of interest for transfection and expression. The nanoparticles typically include a complex of a cationic peptide bound to a protective hydrophilic polymer through a chelator. The nucleic acid is held to the complex by ionic interactions with the cationic peptide. The chelator is adapted to allow release of the hydrophilic polymer in a time frame suitable to facilitate transfection with the nanoparticle at the target cell surface.

Resumen de: US2020056183A1

Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

Resumen de: US2020054886A1

Apparatus and methods are described for use with a heating device (26) configured to heat at least a portion of a subject's body. A nanoparticle (22) is configured to be administered to the subject, the nanoparticle including at least one inner core (30) that includes a magnetic material having a Curie temperature; a phase-change-material layer (31) that surrounds the inner core and that comprises a phase-change material that is configured to absorb latent heat of fusion by undergoing a phase change selected from the group consisting of: solid to liquid, and gel to liquid, the phase-change occurring at a phase-change temperature that is lower than the Curie temperature; and an outer layer (32) disposed around the phase-change-material layer, the outer layer comprising a plurality of nano-subparticles (34) that are separated from one another, such as to form a segmented layer. Other applications are also described.

Resumen de: US2020054559A1

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

Resumen de: US2020054555A1

A contact lens with functional components and products thereof are disclosed, wherein at least one bonding agent is added to the polymeric matrix material of the lens body. The bonding agent can effectively integrate with various kinds of functional components to improve the characteristics of the lens body, increase the comfort of wearing the contact lens, and enhance the ability of water retention. While the user wears the contact lens, the contact lens can release the functional components persistently. Therefore, the present invention can relieve irritations caused by dust, dirt, smoke, and/or pollution from the environment.

Resumen de: US2020054737A1

The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Resumen de: US2020054753A1

A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.

Resumen de: US2020054628A1

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 10 to about 70 weight percent of biocompatible polymers such as a di-block polymer (for example, poly(lactic)acid and polyethylene glycol or poly(lactic)-co-poly (glycolic) acid and poly(ethylene)glycol), about 5 to about 50 weight percent glyceride (for example, a monoglyceride, a diglyceride, or a triglyceride), and about 0.1% to about 40% weight percent therapeutic agent (for example, docetaxel or bortezomib).

Resumen de: US2020054574A1

For applications in drug delivery, “smart” materials have been designed to respond to conditions within microenvironments of tissues or cells. The present invention features stimuli-responsive cross-linked hydrogels that respond to specific metabolites of disease. For example, protein-polymer materials of the present invention are configured to release their drug cargo upon encountering the higher lactate concentrations within tumor microenvironments.

Resumen de: US2020054562A1

The methods of manufacture of a drug delivery composition. In some aspects, the methods include providing an organic phase, a biologically active ingredient, and an aqueous phase with a desirable pH (e.g., a pH at which the active ingredient has increased solubility in the aqueous phase compared to at neutral pH). After mixing of one or more of the aforementioned components, the resultant mixture is processed to provide the desired drug delivery composition.

Resumen de: US2020057048A1

Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer.

Resumen de: US2020055895A1

wherein the definitions of T, Q, R1 and R2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.

Resumen de: US2020054573A1

An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.

Resumen de: US2020054759A1

Provided herein is chitosan dually derivatized with arginine and gluconic acid; and methods of making and using the same, e.g., for gene delivery in vivo.

Resumen de: US2020054752A1

Disclosed herein are nanoparticle-based plasmonic solutions to therapeutic applications employing titanium nitride (TiN) and other non-stoichiometric compounds as the plasmonic material. Current solutions are suboptimal because they require complex shapes, large particle sizes, and a narrow range of sizes, in order to achieve plasmonic resonances in the biological window. The nanoparticles discloses herein provide plasmonic resonances occurring in the biological window even with small sizes, simple shapes, and better size dispersion restrictions. Local heating efficiencies of such nanoparticles outperform currently used Au and transition metal nanoparticles. The use of smaller particles with simpler shapes and better heating efficiencies allows better diffusion properties into tumor regions, larger penetration depth of light into the biological tissue, and the ability to use excitation light of less power.

Resumen de: US2020054718A1

Application for MDR TNBC significantly increasing the efficacy of TNBC treatment and address a global health concern by blocking the ability of mitochondria to fuse together and with other organelles through a nanomedicine therapy. The development of a dual targeted nanomedicine therapy targeting the epidermal growth factor receptor on the surface of TNBC cancers cells and subcellular targeting of mitochondria through mitofusin 2 (MFN2) targeting (mitofusin mediates inter-mitochondrial fusion and fusion of mitochondria with the endoplasmic reticulum). The combination therapy delivers an MFN2-peptidepolymer construct for blocking MFN2 along with a low dose of BAM? (a BAX activator). Transient blocking of MFN2 reduces cellular energy capacity (through decreased mitochondrial fusion), decrease total protein production (by decreased mitochondrial coupling to the endoplasmic reticulum), increases the susceptibility of the cell to paclitaxel or BAM? (increased efficacy of lower dose), with minimal toxicity to normal cells (as IVIFN2 blocking inhibits mitochondrial fusion not mitochondrial function).

Resumen de: US2020055947A1

The present invention provides various compositions and methods useful for the treatment of cancer, including, but not limited to, cancers that are resistant to immune checkpoint blockade and/or are resistant to treatment with PD-1, PD-L1 or CTLA-4 inhibitors. In some embodiments the present invention provides compositions comprising “bi-specific activators”—which are nanoparticles having both a CD40 agonist antibody and an antibody specific for a tumor-associated antigen on their surface. In some embodiments such nanoparticles comprise one or more vaccine adjuvants, for example inside the nanoparticles. The present invention also relates to the use of such compositions in the treatment of tumors.

Resumen de: WO2020036324A1

The present invention relates to a magnetic-field-driven microstructure for delivering a drug and, more specifically, to a microstructure for delivering a drug and a method for producing same, the microstructure being capable of delivering a drug to a particular location as well as withdrawing magnetic nanoparticles out of the body.

Resumen de: EP3611269A1

Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.

Resumen de: WO2018189095A1

The present invention refers to a composition, comprising metallic silver nanoparticles supported on a carrier, the carrier being in the form of particles, wherein the carrier is selected from an inert carrier or an antibiotic, the composition further comprising at least one antibiotic in the case the carrier is an inert carrier. The invention also discloses a nanosystem comprising said composition or a mixture of silver nanoparticles and at least one antibiotic, for use in the treatment of an infection caused by at least one strain of bacteria resistant to at least one antibiotic. The invention further discloses pharmaceutical compositions and methods for the preparation of the compositions and nanosystems.

Resumen de: WO2018170245A1

The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.